264 related articles for article (PubMed ID: 9286751)
1. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
Frith JC; Mönkkönen J; Blackburn GM; Russell RG; Rogers MJ
J Bone Miner Res; 1997 Sep; 12(9):1358-67. PubMed ID: 9286751
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
Mönkkönen J; Taskinen M; Auriola SO; Urtti A
J Drug Target; 1994; 2(4):299-308. PubMed ID: 7858955
[TBL] [Abstract][Full Text] [Related]
3. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ
Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
5. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.
Lehenkari PP; Kellinsalmi M; Näpänkangas JP; Ylitalo KV; Mönkkönen J; Rogers MJ; Azhayev A; Väänänen HK; Hassinen IE
Mol Pharmacol; 2002 May; 61(5):1255-62. PubMed ID: 11961144
[TBL] [Abstract][Full Text] [Related]
6. Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro.
Makkonen N; Hirvonen MR; Teräväinen T; Savolainen K; Mönkkönen J
J Pharmacol Exp Ther; 1996 May; 277(2):1097-102. PubMed ID: 8627521
[TBL] [Abstract][Full Text] [Related]
7. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa.
Oelzner P; Bräuer R; Henzgen S; Thoss K; Wünsche B; Hersmann G; Abendroth K; Kinne RW
Clin Immunol; 1999 Jan; 90(1):79-88. PubMed ID: 9884355
[TBL] [Abstract][Full Text] [Related]
8. The cellular uptake and metabolism of clodronate in RAW 264 macrophages.
Mönkkönen H; Rogers MJ; Makkonen N; Niva S; Auriola S; Mönkkönen J
Pharm Res; 2001 Nov; 18(11):1550-5. PubMed ID: 11758762
[TBL] [Abstract][Full Text] [Related]
9. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.
Makkonen N; Salminen A; Rogers MJ; Frith JC; Urtti A; Azhayeva E; Mönkkönen J
Eur J Pharm Sci; 1999 May; 8(2):109-18. PubMed ID: 10210733
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
Selander KS; Mönkkönen J; Karhukorpi EK; Härkönen P; Hannuniemi R; Väänänen HK
Mol Pharmacol; 1996 Nov; 50(5):1127-38. PubMed ID: 8913344
[TBL] [Abstract][Full Text] [Related]
11. Liposomes for specific depletion of macrophages from organs and tissues.
van Rooijen N; Hendrikx E
Methods Mol Biol; 2010; 605():189-203. PubMed ID: 20072882
[TBL] [Abstract][Full Text] [Related]
12. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro.
Mönkkönen J; Urtti A; Paronen P; Elo HA; Ylitalo P
Drug Metab Dispos; 1989; 17(6):690-3. PubMed ID: 2575509
[TBL] [Abstract][Full Text] [Related]
13. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
[TBL] [Abstract][Full Text] [Related]
15. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron.
Mönkkönen J; Heath TD
Calcif Tissue Int; 1993 Aug; 53(2):139-46. PubMed ID: 8402323
[TBL] [Abstract][Full Text] [Related]
16. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages.
van Rooijen N
J Drug Target; 2008 Aug; 16(7):529-34. PubMed ID: 18686122
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
18. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
19. Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid.
Van Rooijen N; Sanders A
Hepatology; 1996 May; 23(5):1239-43. PubMed ID: 8621159
[TBL] [Abstract][Full Text] [Related]
20. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
